[Cytoarchitectonics and parameters of aggregation of erythrocytes in patients with acute myocardial infarction].
OBJECTIVE
To assess cytoarchitectonics and parameters of aggregation of erythrocytes in patients with acute myocardial infarction, to elucidate their relationships with risk factors of ischemic heart disease.


METHODS
We examined 80 patients with acute myocardial infarction, 20 patients with stable angina pectoris comprised control group. Patients were divided into subgroups according to depth of damage of the myocardium and presence of statins in the treatment scheme. Examination included assessment of cytoarchitectonics and parameters of aggregation of erythrocytes, determination of blood plasma lipid spectrum and concentration of fibrinogen.


CONCLUSIONS
Pronounced pathological changes of cytoarchitectonics of erythrocytes and parameters of their aggregation develop in acute myocardial infarction. These changes increase with increase of depth of myocardial damage. Inclusion of statins in the scheme of treatment leads to significant improvement of the parameters studied. This improvement is more pronounced in patients with non-Q-wave myocardial infarction. Presence of significant interrelationships between cytoarchitectonics of erythrocytes and their aggregation and levels of low density lipoprotein cholesterol, concentration of fibrinogen.
Berezin
M V
MV
Dovgaliuk
Iu V
IuV
Lutaiĭ
A V
AV
Berezina
A M
AM
Kodin
A V
AV
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology*
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors